Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Ioannis Ntanasis-Stathopoulos and Meletios Dimopoulos.
  1. Rare manifestations of extramedullary myeloma: testicular plasmacytomas. Leuk Lymphoma. 2018 08; 59(8):2002-2004.
    View in: PubMed
    Score: 0.745
  2. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021 08 02; 11(8):138.
    View in: PubMed
    Score: 0.240
  3. Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells. 2021 07 30; 10(8).
    View in: PubMed
    Score: 0.240
  4. Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clin Exp Med. 2021 Jul 20.
    View in: PubMed
    Score: 0.239
  5. High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines (Basel). 2021 Jul 01; 9(7).
    View in: PubMed
    Score: 0.238
  6. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021 07 01; 137(26):3674-3676.
    View in: PubMed
    Score: 0.238
  7. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier? Am J Hematol. 2021 09 01; 96(9):E321-E324.
    View in: PubMed
    Score: 0.237
  8. SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. Eur J Intern Med. 2021 07; 89:87-96.
    View in: PubMed
    Score: 0.236
  9. SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. Hemasphere. 2021 Mar; 5(3):e547.
    View in: PubMed
    Score: 0.232
  10. COVID-19: time to flatten the infodemic curve. Clin Exp Med. 2021 May; 21(2):161-165.
    View in: PubMed
    Score: 0.231
  11. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021 May; 21(2):167-179.
    View in: PubMed
    Score: 0.228
  12. Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020 Nov; 20(4):493-506.
    View in: PubMed
    Score: 0.224
  13. Hematological findings and complications of COVID-19. Am J Hematol. 2020 07; 95(7):834-847.
    View in: PubMed
    Score: 0.221
  14. Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. Ann Hematol. 2019 Jun; 98(6):1427-1434.
    View in: PubMed
    Score: 0.203
  15. Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studies. Int J Cancer. 2019 07 15; 145(2):347-359.
    View in: PubMed
    Score: 0.202
  16. Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. Int J Cancer. 2019 07 15; 145(2):559-568.
    View in: PubMed
    Score: 0.201
  17. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. Amyloid. 2018 Dec; 25(4):234-241.
    View in: PubMed
    Score: 0.201
  18. Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. Leuk Lymphoma. 2019 03; 60(3):619-628.
    View in: PubMed
    Score: 0.201
  19. How I treat rituximab refractory patients with WM. Oncotarget. 2018 Dec 07; 9(96):36824-36825.
    View in: PubMed
    Score: 0.200
  20. Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. Blood Cancer J. 2018 05 11; 8(5):42.
    View in: PubMed
    Score: 0.192
  21. Alcohol consumption and risk of hematological malignancies: A meta-analysis of prospective studies. Int J Cancer. 2018 08 01; 143(3):486-495.
    View in: PubMed
    Score: 0.190
  22. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018 01 12; 8(1):7.
    View in: PubMed
    Score: 0.188
  23. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood. 2018 01 25; 131(4):464-467.
    View in: PubMed
    Score: 0.186
  24. Consumption of fruits, vegetables, and risk of hematological malignancies: a systematic review and meta-analysis of prospective studies. Leuk Lymphoma. 2018 02; 59(2):434-447.
    View in: PubMed
    Score: 0.183
  25. Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases. Leuk Lymphoma. 2018 04; 59(4):983-987.
    View in: PubMed
    Score: 0.182
  26. Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. J Infect. 2021 07; 83(1):1-16.
    View in: PubMed
    Score: 0.059
  27. Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. Microorganisms. 2021 Mar 06; 9(3).
    View in: PubMed
    Score: 0.058
  28. Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses. 2020 12 25; 13(1).
    View in: PubMed
    Score: 0.058
  29. Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. Microorganisms. 2020 Nov 28; 8(12).
    View in: PubMed
    Score: 0.057
  30. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020 08; 34(8):2000-2011.
    View in: PubMed
    Score: 0.055
  31. Meat, fish, dairy products and risk of hematological malignancies in adults - a systematic review and meta-analysis of prospective studies. Leuk Lymphoma. 2019 08; 60(8):1978-1990.
    View in: PubMed
    Score: 0.051
  32. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2018 06; 18(6):431-437.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.